There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug ...

NICE’s final draft guidance (published Friday 3 May 2024), recommends voxelotor (also called Oxbryta and made by Pfizer) with or without another treatment for SCD called hydroxycarbamide.

The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...

The following considerations around implementing the evidence generation process have been identified through working with system partners: ...

Colostomy surgery is an operation to divert 1 or both ends of the colon through an opening in the abdomen (NHS, 2020). A bag (also known as a pouch or appliance) can be placed over the stoma to ...

Pembrolizumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had at least 2 previous treatments and cannot have an ...

NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not ...

NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence ...

The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...

The heart needs a constant supply of blood. In coronary heart disease, this blood supply gets interrupted or blocked by a build-up of fatty substances in the coronary arteries. Drug eluting stents are ...

If data collection is expected to end later than planned, the company should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance if ...